Suvorexant

Belsomra (suvorexant) is a small molecule pharmaceutical. Suvorexant was first approved as Belsomra on 2014-08-13. It is used to treat sleep initiation and maintenance disorders in the USA. The pharmaceutical is active against orexin receptor type 1 and orexin receptor type 2. Belsomra's patents are valid until 2033-05-29 (FDA).